WCN23-0372 ASSESSMENT OF DRUG INTERACTIONS WITH IPTACOPAN

Iptacopan (LNP023) is a first-in-class, oral, low molecular weight, Factor B inhibitor being developed for the treatment of diseases associated with activation alternative complement pathway. Current Phase III studies iptacopan include paroxysmal nocturnal hemoglobinuria, C3 glomerulonephritis, IgA nephropathy, and atypical hemolytic uremic syndrome. Preclinical identified CYP2C8, OATP P-gp as three potential sources drug-drug interaction either victim or perpetrator.